Reversible addition-fragmentation chain transfer (RAFT) is considered to be one of most famous reversible deactivation radical polymerization protocols. Benefiting from its living or controlled polymerization process, complex polymeric architectures with controlled molecular weight, low dispersity, as well as various functionality have been constructed, which could be applied in wide fields, including materials, biology, and electrology. Under the continuous research improvement, main achievements have focused on the development of new RAFT techniques, containing fancy initiation methods (e.g., photo, metal, enzyme, redox and acid), sulfur-free RAFT system and their applications in many fields. This review summarizes the current advances in major bright spot of novel RAFT techniques as well as their potential applications in the optoelectronic field, especially in the past a few years.

Topological insulators (TIs) are a new quantum phase of matter with topologically protected surface metallic states inside the insulating bulk states. Due to their unique single Dirac cone surface state, relatively low sheet resistance, and broadband optical operation, they have attracted enormous interests in both electronics and optics. Out of those above‐mentioned applications, electronic devices are seeking most attention until now. Here the experimental prototype for light processing device, TI‐coated microfiber (TCM), is demonstrated. Owing to the large Kerr coefficient of TI, TCM could operate as an effective optical Kerr switcher and broadband wavelength converter at the telecommunication band. This device could be well integrated with current high‐speed fiber optic communication networks and might well provide an approach for all‐optical signal processing through nonlinear processes. It is anticipated that few‐layer topological insulator might afford new opportunities for nonlinear photonic applications, especially in all‐optical routing, optical multiplication frequency, etc.

VV116 (JT001) is an oral drug candidate of nucleoside analog against SARS-CoV-2. The purpose of the three phase I studies was to evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending oral doses of VV116 in healthy subjects, as well as the effect of food on the pharmacokinetics and safety of VV116. Three studies were launched sequentially: Study 1 (single ascending-dose study, SAD), Study 2 (multiple ascending-dose study, MAD), and Study 3 (food-effect study, FE). A total of 86 healthy subjects were enrolled in the studies. VV116 tablets or placebo were administered per protocol requirements. Blood samples were collected at the scheduled time points for pharmacokinetic analysis. 116-N1, the metabolite of VV116, was detected in plasma and calculated for the PK parameters. In SAD, AUC and Cmax increased in an approximately dose-proportional manner in the dose range of 25–800 mg. T1/2 was within 4.80–6.95 h. In MAD, the accumulation ratio for Cmax and AUC indicated a slight accumulation upon repeated dosing of VV116. In FE, the standard meal had no effect on Cmax and AUC of VV116. No serious adverse event occurred in the studies, and no subject withdrew from the studies due to adverse events. Thus, VV116 exhibited satisfactory safety and tolerability in healthy subjects, which supports the continued investigation of VV116 in patients with COVID-19.

No abstract

No abstract

No abstract

No abstract

No abstract